Are there new guidelines for kidney cancer based on recent 2025 trials?
The European Association of Urology (EAU) released updated guidelines for renal cell carcinoma (kidney cancer) in 2025, based on a structured literature search through May 2024 7. These guidelines incorporate recent trial results and offer new recommendations across several areas of kidney cancer management. While the 2025 update does not cite specific 2025 trials, it reflects evidence from studies published up to 2024, including long-term follow-up from landmark trials like CheckMate 214 6.
What the research says
The 2025 EAU guidelines include several key updates 7. For localized kidney cancer, there are new recommendations on the use of stereotactic body radiotherapy (SBRT), a precise radiation technique. The guidelines also provide updated advice on adjuvant therapy (treatment given after surgery to reduce the risk of cancer returning). For advanced clear-cell renal cell carcinoma, the guidelines revise recommendations for systemic therapy in later lines of treatment. Additionally, a new chapter on hereditary RCC has been added, addressing genetic forms of the disease. These updates are based on a comprehensive review of meta-analyses, systematic reviews, and randomized controlled trials (RCTs) published up to May 2024 7. One important trial informing the guidelines is the CheckMate 214 study, which with 8-year follow-up showed that the combination of nivolumab plus ipilimumab improved overall survival compared to sunitinib in intermediate/poor-risk advanced RCC patients (hazard ratio 0.69) 6. A separate systematic review of 2025 RCTs in genitourinary cancers identified nine kidney cancer trials, but the EAU guidelines were finalized before these results were available 4. Therefore, while the 2025 guidelines are current, they may not yet reflect the very latest 2025 trial data.
What to ask your doctor
- What do the 2025 EAU guidelines mean for my specific type and stage of kidney cancer?
- Is stereotactic body radiotherapy (SBRT) a treatment option for my localized kidney cancer?
- Should I consider adjuvant therapy after surgery based on the updated recommendations?
- If I have advanced clear-cell RCC, what are the latest systemic therapy options according to the 2025 guidelines?
- Do I need genetic testing or counseling for hereditary kidney cancer, as mentioned in the new guidelines?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.